moa of glp-1 agonists Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms action Non-insulin injectable antidiabetic drugs -

Discover what current research and FDA findings reveal about mental health risks with semaglutide, tirzepatide, and other GLP-1 medications for diabetes and weight management.

Methods Adults (18 years old) with T2D required at least one prescription for injectable semaglutide at index date (treatment switch), at least one prescription for any other GLP-1 RA in the previous 365 days, a baseline HbA1c and/or weight measurement in the 90 days pre-index and a follow-up measurement at 180 and 365 days post-index

or oral administration

These findings support their use as a valuable adjunctive obesity management medication (OMMs) in post-bariatric care, though long-term adherence and cost-effectiveness require further investigation

Recently, a drug targeting the receptors of both GLP-1 and glucose-dependent insulinotropic polypeptide ...